<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR1800015353</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2018-03-25</date_registration>
      <primary_sponsor>Department of hematology, Xinqiao hospital, Army Medical University</primary_sponsor>
      <public_title>Clinical study on prophylactic infusin of CAR-T cells  in preventing relapse of acute lymphoblatic leuekmia after allogeneic stem cell transplantation </public_title>
      <acronym />
      <scientific_title>Effect of prophylactic infusin of CAR-T cells  in preventing relapse of acute lymphoblatic leuekmia after allogeneic stem cell transplantation: A phase I, non-blind, non-control,single-central study</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2018-03-12</date_enrolment>
      <type_enrolment />
      <target_size>Case series:33;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=26164</url>
      <study_type>Treatment study</study_type>
      <study_design>Case series</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>B-cell acute lymphoblastic leukemia </hc_freetext>
      <i_freetext>Case series:CAR-T cell;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Zhang  Cheng</firstname>
        <middlename />
        <lastname />
        <address>Department of hematology, Xinqiao hospital, Army Medical University</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 023-68774209</telephone>
        <email>chzhang2014@163.com</email>
        <affiliation>Department of hematology, Xinqiao hospital, Army Medical University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Zhang Cheng</firstname>
        <middlename />
        <lastname />
        <address>Department of hematology, Xinqiao hospital, Army Medical University</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 023-687774209</telephone>
        <email>chzhang2014@163.com</email>
        <affiliation>Department of hematology, Xinqiao hospital, Army Medical University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. The patients with the B-cell acute lymphoblast leukemia with molecular relapse after allogeneic hematopoietic stem cell transplantation with CD19 expression;
2. no GVHD, Male or Femal with any ages;
3. The estimated survival is over three months;
4. ECOG performance status of &lt;=2 at study entry;
5. The important organs are function,such as heart and brain. </inclusion_criteria>
      <agemin />
      <agemax />
      <gender>Both</gender>
      <exclusion_criteria>1. The uncontroled infection. HBV and HCV are positive;
2. The patients received any cell immunotherapy in the past. </exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>One-year disease-free survival;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>One-year disease-free overalsurvival;GVHD;Infection;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Found by the key clinical foundation of Xinqiao Hospital, Army Medical Univsesity</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-03-11</approval_date>
        <contact_name>Chinese Clinical Trial Registry Hong Kong Center, Kowloon Tong Hong Kong Baptist University, Hong Kong SR, China</contact_name>
        <contact_address>Chinese Clinical Trial Registry Hong Kong Center, Kowloon Tong Hong Kong Baptist University, Hong Kong SR, China</contact_address>
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>